Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1797-1804

  Strohmeyer, Dagmar ^a,e   Strauß, Franz ^b   Rössing, Christian ^b   Roberts, Chris ^c   Kaufmann, Olaf ^b   Bartsch, Georg ^a   Effert, Peter ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Div of Epidemiol and Biostatistics   (Italy)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Angiogenesis; BFGF; C met; Progression; Prostate cancer; VEGF

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MICROVESSEL DENSITY; OUTCOMES RESEARCH; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; TISSUE SECTION;

FACTOR VIII; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PARAFFIN EMBEDDING; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3242670740     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Srivastava A, Laidler P, Davies RP, Horgan K and Hughes LE: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.00 mm) skin melanoma. Am J Pathol 133: 419-423, 1988.
2. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
3. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN and Harris AL: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74: 762-766, 1994.
4. Jaeger TM, Weidner N, Chew K, Moore DH, Kershman RL, Waldman FM and Carroll PR: Tumor angiogenesis correlates with lymph node metastasis in invasive bladder cancer. J Urol 154: 69-71, 1994.
5. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
6. Brawer MK: Quantitative microvessel density: A staging and prognostic marker in human prostate carcinoma. Cancer 78: 345-349, 1996.
7. Lissbrant IF, Stattin P, Damber JE and Bergh A: Vascular density is a predictor of cancer specific survival in prostatic carcinoma. Prostate 33: 38-45, 1997.
8. Strohmeyer D, Rössing C, Strauss F, Bauerfeind A, Kaufmann O and Loening SA: Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 42: 26-33, 2000.
9. Van Moorselaar RJ and Voest EE: Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 197: 239-250, 2002.
10. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ and Dinney CP: Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 5: 783-789, 1999.
11. Melnyk O, Zimmerman M, Kim KJ and Shuman M: Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in preclinical model. J Urol 161: 960-963, 1999.
12. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ and Griffiths K: Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 74: 910-916, 1996.
13. Strohmeyer D, Rössing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G and Loening SA: Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45: 216-224, 2000.
14. Zhu X and Humphrey PA: Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 56: 1071-1074, 2000.
15. Ozen M, Giri D, Ropiquet F, Mansukhani A and Ittmann M: Role of fibroblast growth factor receptor signalling in prostate cancer cell survival. J Natl Cancer Inst 93: 1783-1790, 2001.
16. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL and Vande Woude GF: High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60: 1113-1117, 2002.
17. Mydlo JH, Kral JG and Macchia RJ: Differences in prostate and adipose tissue basic fibroblast growth factor: analysis of preliminary results. Urology 50: 472-478, 1997.
18. Walsh K, Sherwood RA, Dew TK and Mulvin D: Angiogenic peptides in prostatic disease. BJU Int 84: 1081-1083, 1999.
19. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER and Rimm DL: Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82: 1513-1520, 1998.
20. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude GF and Knudsen BS: Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159: 579-590, 2001.
21. Schroeder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK and Pavone-Macaluso M: The TNM classification of prostate cancer. Prostate (Suppl.) 4: 129-138, 1992.
22. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
23. Kollermann J and Helpap B: Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant and malignant prostate tissue. Am J Clin Pathol 116: 115-121, 2001.
24. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A and Biagini G: Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45: 72-79, 2000.
25. Kwak C, Jin RJ, Lee C, Park MS and Lee SE: Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 89: 303-309, 2002.
26. Giri D, Ropiquet F and Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071, 1999.
27. Polnaszek N, Kwabi-Addo B, Petersen LE, Ozen M, Greenberg NM, Ortega S, Basilico C and Ittmann M: Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 63: 5754-5760, 2003.
28. Dorkin TJ, Robinson MC, Marsh C, Neal DE and Leung HY: aFGF immunoreactivity in prostate cancer and its colocalization with bFGF and FGF 8. J Pathol 189: 564-569, 1999.
29. Nakashiro K, Hayashi Y and Oyasu R: Immunohistochemical expression of hepatocyte growth factor and c-met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10: 1149-1153, 2003.
30. Watanabe M, Fukutome K, Kato H, Murata M, Kawamura J, Shiraishi T and Yatani R: Progression-linked overexpression of c-met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 141: 173-178, 1999.
31. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B and Muller KM: Hepatocyte growth factor/scatter factor and its receptor c-met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. Cancer Res Clin Oncol 124: 291-296, 1998.
32. Wagatsuma S, Konno R, Sato S and Yajima A: Tumor angiogenesis, hepatocyte growth factor and c-met expression in endometrial carcinoma. Cancer 82: 520-530, 1998.
33. Camp RL, Rimm EB and Rimm DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86: 2259-2265, 1999.